An Activatable and Covalent Tumor-Associated Antigen Capturer Enabling Systemic Injection In Vivo for Promoted Antitumor Immunity

generation capability and TAA capture efficiency, leading to significant tumor growth inhibition. Moreover, the captured TAAs and TLR agonists synergistically activate adaptive antitumor immunity, as evidenced by their potentiated T cell responses. These findings highlight the critical role of TME-activatable covalent antigen capture in enabling systemic delivery of antigen-capturing nanomaterials and validate TDR848@FPB as a versatile platform for precise cancer immunotherapy with a high therapeutic outcome and low off-target effects, independent of tumor localized administration.